AssetMark Inc
DFTX

AssetMark Inc’s Definium Therapeutics DFTX Stock Holding History

AssetMark Inc’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7M Buy
+396,542
New +$9.8M 0.03% 377
2023
Q3 		– Sell
-8
Closed -$29 – 1786
2023
Q2 		$29 Buy
+8
New +$28 ﹤0.01% 1549

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AssetMark Inc's DFTX Position: Q2 2026 in Review

AssetMark Inc opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 396,542 shares worth $18.7M. The stake represents 0.03% of the portfolio and ranks #377 among its holdings. This is a return to the name: AssetMark Inc previously reported a position in DFTX as recently as Q2 2023.

AssetMark Inc first reported a position in DFTX in Q2 2023 and has held it in 2 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • AssetMark Inc held 396,542 shares of Definium Therapeutics worth $18.7M as of Q2 2026.
  • Definium Therapeutics was a new AssetMark Inc position in Q2 2026.
  • Definium Therapeutics made up 0.03% of AssetMark Inc's portfolio in Q2 2026, its #377 holding.
  • AssetMark Inc first reported a position in Definium Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.